Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$MCET Great Income per year! Look here! https://investorshub.advfn.com/boards/read_msg.aspx?message_id=161288888
Market Makers on radar! LONG confirmed! More and More VOLUME! https://investorshub.advfn.com/MultiCell-Technologies-MCET-2694/
Market Makers on radar! LONG confirmed! More and More VOLUME! https://investorshub.advfn.com/MultiCell-Technologies-MCET-2694/
$GSFI Green Stream Holdings Anticipates Sunny Forecast for Renewable Energy - Market Rally as U.S. Stocks Soar Just Hours Before Biden Inauguration
JAN 20, 2021 11:59AM EST
Malibu, California--(Newsfile Corp. - January 20, 2021) - Green Stream Holdings Inc. (OTC PINK: GSFI) ("the Company") ("Green Stream") (http://www.GreenRainSolar.com ), an emerging leader in the solar utility and finance space, announces today what it believes to be a new era for Renewable Energy and its Solar Utilities/Financing model as stocks rise in advance of the inauguration of Joe Biden as the 46th President of the United States.
To view an enhanced version of this graphic, please visit: https://orders.newsfilecorp.com/files/6720/72426_c77e571b24d93902_002full.jpg
Biden's agenda is to transition the U.S. from an economy reliant on fossil fuels to one driven by wind, solar and other renewable-energy sources. The shift from fossil-fuel companies to renewable-energy firms accelerated during the Trump administration, despite the president's vows to support the U.S. coal and petroleum industries.
Big and small investors have moved their assets away from fossil-fuel producers and toward renewable energy companies. Big investors like BlackRock Inc., the world's largest asset manager, overseeing $7.8 trillion, have said they plan to take into account corporations' disclosures of environmental risks, including carbon footprints.
According to Wells Fargo senior market strategist Scott Wren, "Since the start of the year, cyclicals have outperformed, with energy gaining the most, up 15%, helped by higher oil prices. Financials were up 5.1%, and materials were up 4.4%."
"All of these cyclicals stocks have moved in advance of what we think will be a higher rate move. Rates have moved up to support that idea," Wilson said. "We think they could go up quite a bit more over the course of the next several months."
As well, The iShares Global Clean Energy ETF, which tracks S&P Global's index of clean energy companies around the world, has risen by nearly 30% since July 2020. The fund's assets under management swelled to $1.2 billion from $431 million at the start of the year.
GSFI CEO Eric Fain is encouraged by the increased opportunity Biden's new agenda could mean for companies like Green Stream Holdings. "I believe we are at the dawn of a new era for renewable energy and, in turn, an increased access to market with ability to expedite shareholder value as we cultivate new opportunities alongside our current projects in New York, including:
160 Imlay street. Brooklyn Ny
8012 Tonelle Ave; North Bergen, NJ
44 Victory Blvd; Staten Island, NY
111 Station Road; Bellport, NY
15-17 Sherwood Ave - Yonkers Proposal
4290 Austin Blvd; Island Park, NY
"We have recently moved our headquarters to a functional work/living space which belongs to our flagship project at 160 Imlay Street in Brooklyn, New York, where our utility/financing model can be seen in action as we continue to develop opportunities in the NE United States and beyond."
Project To view an enhanced version of this graphic, please visit: https://orders.newsfilecorp.com/files/6720/72426_c77e571b24d93902_003full.jpg
"This is all in line with NY Governor Cuomo's recent announcement of a clean energy initiative which unveiled the details of the awards for 21 large-scale solar, wind, and energy storage projects across upstate New York, totaling 1,278 megawatts of new renewable capacity," states Fain.
Shareholders-visit greenrainsolar.com. where you can view Green Stream's news, filings and even a live Level 2 stream, along with other company information.
Cannot view this image? Visit: https://orders.newsfilecorp.com/files/6720/72426_c77e571b24d93902_004.jpg GSFI - Strategic Moves To view an enhanced version of this graphic, please visit: https://orders.newsfilecorp.com/files/6720/72426_c77e571b24d93902_004full.jpg
https://www.nasdaq.com/press-release/green-stream-holdings-anticipates-sunny-forecast-for-renewable-energy-market-rally-as
$GSFI Green Stream Holdings Anticipates Sunny Forecast for Renewable Energy - Market Rally as U.S. Stocks Soar Just Hours Before Biden Inauguration
JAN 20, 2021 11:59AM EST
Malibu, California--(Newsfile Corp. - January 20, 2021) - Green Stream Holdings Inc. (OTC PINK: GSFI) ("the Company") ("Green Stream") (http://www.GreenRainSolar.com ), an emerging leader in the solar utility and finance space, announces today what it believes to be a new era for Renewable Energy and its Solar Utilities/Financing model as stocks rise in advance of the inauguration of Joe Biden as the 46th President of the United States.
To view an enhanced version of this graphic, please visit: https://orders.newsfilecorp.com/files/6720/72426_c77e571b24d93902_002full.jpg
Biden's agenda is to transition the U.S. from an economy reliant on fossil fuels to one driven by wind, solar and other renewable-energy sources. The shift from fossil-fuel companies to renewable-energy firms accelerated during the Trump administration, despite the president's vows to support the U.S. coal and petroleum industries.
Big and small investors have moved their assets away from fossil-fuel producers and toward renewable energy companies. Big investors like BlackRock Inc., the world's largest asset manager, overseeing $7.8 trillion, have said they plan to take into account corporations' disclosures of environmental risks, including carbon footprints.
According to Wells Fargo senior market strategist Scott Wren, "Since the start of the year, cyclicals have outperformed, with energy gaining the most, up 15%, helped by higher oil prices. Financials were up 5.1%, and materials were up 4.4%."
"All of these cyclicals stocks have moved in advance of what we think will be a higher rate move. Rates have moved up to support that idea," Wilson said. "We think they could go up quite a bit more over the course of the next several months."
As well, The iShares Global Clean Energy ETF, which tracks S&P Global's index of clean energy companies around the world, has risen by nearly 30% since July 2020. The fund's assets under management swelled to $1.2 billion from $431 million at the start of the year.
GSFI CEO Eric Fain is encouraged by the increased opportunity Biden's new agenda could mean for companies like Green Stream Holdings. "I believe we are at the dawn of a new era for renewable energy and, in turn, an increased access to market with ability to expedite shareholder value as we cultivate new opportunities alongside our current projects in New York, including:
160 Imlay street. Brooklyn Ny
8012 Tonelle Ave; North Bergen, NJ
44 Victory Blvd; Staten Island, NY
111 Station Road; Bellport, NY
15-17 Sherwood Ave - Yonkers Proposal
4290 Austin Blvd; Island Park, NY
"We have recently moved our headquarters to a functional work/living space which belongs to our flagship project at 160 Imlay Street in Brooklyn, New York, where our utility/financing model can be seen in action as we continue to develop opportunities in the NE United States and beyond."
Project To view an enhanced version of this graphic, please visit: https://orders.newsfilecorp.com/files/6720/72426_c77e571b24d93902_003full.jpg
"This is all in line with NY Governor Cuomo's recent announcement of a clean energy initiative which unveiled the details of the awards for 21 large-scale solar, wind, and energy storage projects across upstate New York, totaling 1,278 megawatts of new renewable capacity," states Fain.
Shareholders-visit greenrainsolar.com. where you can view Green Stream's news, filings and even a live Level 2 stream, along with other company information.
Cannot view this image? Visit: https://orders.newsfilecorp.com/files/6720/72426_c77e571b24d93902_004.jpg GSFI - Strategic Moves To view an enhanced version of this graphic, please visit: https://orders.newsfilecorp.com/files/6720/72426_c77e571b24d93902_004full.jpg
https://www.nasdaq.com/press-release/green-stream-holdings-anticipates-sunny-forecast-for-renewable-energy-market-rally-as
$MCET MultiCell has licensed several pharmaceutical companies rights to use the Fa2N-4 cell line for drug toxicity applications including Pfizer, Bristol-Myers Squibb, and Eisai Pharmaceuticals. MultiCell licensed Corning, Inc. to sell the Fa2N-4 cell line and media within the drug discovery and life science research markets for drug toxicity (Tox) applications as well as for drug adsorption, distribution, metabolism and excretion (ADME) studies.
MultiCell retained worldwide exclusive ownership of the Fa2N-4 and Ea1C-35 cell lines for all applications other than ADME/Tox, including drug target identification and using the cell lines for the production of therapeutic plasma proteins.
https://www.thefreelibrary.com/MultiCell+Technologies+is+granted+United+States+Patent+for...-a0214398995
$MCET MultiCell has licensed several pharmaceutical companies rights to use the Fa2N-4 cell line for drug toxicity applications including Pfizer, Bristol-Myers Squibb, and Eisai Pharmaceuticals. MultiCell licensed Corning, Inc. to sell the Fa2N-4 cell line and media within the drug discovery and life science research markets for drug toxicity (Tox) applications as well as for drug adsorption, distribution, metabolism and excretion (ADME) studies.
MultiCell retained worldwide exclusive ownership of the Fa2N-4 and Ea1C-35 cell lines for all applications other than ADME/Tox, including drug target identification and using the cell lines for the production of therapeutic plasma proteins.
https://www.thefreelibrary.com/MultiCell+Technologies+is+granted+United+States+Patent+for...-a0214398995
$MCET Acknowledgments: We thank Ronald A. Faris, Jin Liu, Stephanie Cascio, Henry Santangini, Kathy Garcia, and Paul Silva of MultiCell Technologies for the Fa2N-4 clone and the scientific collaborations; Sharon Ripp of Pfizer Groton Laboratories for contribution to CYP3A4 enzyme activity data; Teresa Jenkinson and Mike Banker of Pfizer Groton Laboratories for the photomicrograph of the Fa2N-4 cells; Kelly Longo of Pfizer Strategic Alliances for support; and Bo Feng, Ronald Scott Obach, and Ted Liston of Pfizer Groton Laboratories for suggestions and critical reading of this manuscript.
Induction of Drug Metabolism Enzymes and MDR1 Using a Novel Human Hepatocyte Cell Line
https://s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/821/original/303.full.pdf?1539359418
$MCET Acknowledgments: We thank Ronald A. Faris, Jin Liu, Stephanie Cascio, Henry Santangini, Kathy Garcia, and Paul Silva of MultiCell Technologies for the Fa2N-4 clone and the scientific collaborations; Sharon Ripp of Pfizer Groton Laboratories for contribution to CYP3A4 enzyme activity data; Teresa Jenkinson and Mike Banker of Pfizer Groton Laboratories for the photomicrograph of the Fa2N-4 cells; Kelly Longo of Pfizer Strategic Alliances for support; and Bo Feng, Ronald Scott Obach, and Ted Liston of Pfizer Groton Laboratories for suggestions and critical reading of this manuscript.
Induction of Drug Metabolism Enzymes and MDR1 Using a Novel Human Hepatocyte Cell Line
https://s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/821/original/303.full.pdf?1539359418
$MCET "Gold Standard": Evaluation of a Novel Renewable Hepatic Cell Model for Prediction of Clinical CYP3A4 Induction Using a Correlation-Based RIS Approach
Jin Liu, Ronald A Faris
Abstract
Metabolism enzyme induction-mediated drug-drug interactions need to be carefully characterized in vitro for drug candidates in order to predict in vivo outcomes of safety risk and therapeutic efficiency. Currently, both the FDA and EMA recommend using primary human hepatocytes as the "Gold Standard" in vitro test system for studying the induction potential of candidate drugs on cytochrome P450 (CYP), CYP3A4, CYP1A2, and CYP2B6. However, primary human hepatocytes are known to bear inherent limitations such as limited supply and large lot-to-lot variations which result in an experimental burden to qualify new lots. To overcome these shortcomings, a renewable source of human hepatocytes (i.e., Corning HepatoCells) was developed from primary human hepatocytes and was evaluated for in vitro CYP3A4 induction using methods well established by pharmaceutical industry HepatoCells have shown mature hepatocyte-like morphology, demonstrated primary hepatocyte-like response to prototypical inducers of all 3 CYP enzymes with excellent consistency. Importantly, HepatoCells retain a phenobarbital responsive nuclear translocation of human CAR from the cytoplasm, characteristic to primary hepatocytes. To validate HepatoCells as a useful tool to predict potential clinical relevant CYP3A4 induction, we tested three different lots of HepatoCells with a group of clinical strong, moderate/weak CYP3A4 inducers, and non-inducers. A relative induction score (RIS) calibration curve based approach was used for prediction. HepatoCells showed accurate prediction comparable to primary human hepatocytes. Together, these results demonstrate that Corning HepatoCells is a reliable in vitro model for drug-drug interaction studies during the early phase of drug testing.
https://dmd.aspetjournals.org/content/early/2017/01/06/dmd.116.072124
https://dmd.aspetjournals.org/content/dmd/early/2017/01/06/dmd.116.072124.full.pdf
Currently, both the FDA and EMA recommend using primary human hepatocytes as the "Gold Standard" in vitro test system for studying the induction potential of candidate drugs on cytochrome P450 (CYP), CYP3A4, CYP1A2, and CYP2B6.
Fa2N-4 Multicell Technologies / Xenotech Patents
Inventor: Jin Liu, Ronald A Faris
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=161330062
$MCET "Gold Standard": Evaluation of a Novel Renewable Hepatic Cell Model for Prediction of Clinical CYP3A4 Induction Using a Correlation-Based RIS Approach
Jin Liu, Ronald A Faris
Abstract
Metabolism enzyme induction-mediated drug-drug interactions need to be carefully characterized in vitro for drug candidates in order to predict in vivo outcomes of safety risk and therapeutic efficiency. Currently, both the FDA and EMA recommend using primary human hepatocytes as the "Gold Standard" in vitro test system for studying the induction potential of candidate drugs on cytochrome P450 (CYP), CYP3A4, CYP1A2, and CYP2B6. However, primary human hepatocytes are known to bear inherent limitations such as limited supply and large lot-to-lot variations which result in an experimental burden to qualify new lots. To overcome these shortcomings, a renewable source of human hepatocytes (i.e., Corning HepatoCells) was developed from primary human hepatocytes and was evaluated for in vitro CYP3A4 induction using methods well established by pharmaceutical industry HepatoCells have shown mature hepatocyte-like morphology, demonstrated primary hepatocyte-like response to prototypical inducers of all 3 CYP enzymes with excellent consistency. Importantly, HepatoCells retain a phenobarbital responsive nuclear translocation of human CAR from the cytoplasm, characteristic to primary hepatocytes. To validate HepatoCells as a useful tool to predict potential clinical relevant CYP3A4 induction, we tested three different lots of HepatoCells with a group of clinical strong, moderate/weak CYP3A4 inducers, and non-inducers. A relative induction score (RIS) calibration curve based approach was used for prediction. HepatoCells showed accurate prediction comparable to primary human hepatocytes. Together, these results demonstrate that Corning HepatoCells is a reliable in vitro model for drug-drug interaction studies during the early phase of drug testing.
https://dmd.aspetjournals.org/content/early/2017/01/06/dmd.116.072124
https://dmd.aspetjournals.org/content/dmd/early/2017/01/06/dmd.116.072124.full.pdf
Currently, both the FDA and EMA recommend using primary human hepatocytes as the "Gold Standard" in vitro test system for studying the induction potential of candidate drugs on cytochrome P450 (CYP), CYP3A4, CYP1A2, and CYP2B6.
Fa2N-4 Multicell Technologies / Xenotech Patents
Inventor: Jin Liu, Ronald A Faris
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=161330062
$MCET Seven Patents Active: Multicell Technologies, Rhode Island Hospital and Xenotech ( SEKISUI XenoTech )
One Patent Multicell Technologies Receives Stem Cell Patent Active!
Inventor: Ronald A. Faris
Current Assignee: Rhode Island Hospital
US7935528 B2
Application granted
Status Active
2022-10-21 Adjusted expiration
https://patents.google.com/patent/US7935528B2/en?oq=7%2c935%2c528
The invention provides a primary liver stem cell and a cell doublet consisting of a hepatocyte and the stem cell, both of which are derived from normal liver tissue. Methods of isolating the cells, genetically altering the cells, and using the cells for transplantation are also within the invention.
https://www.patentdocs.org/2011/07/patent-profile-multicell-technologies-receives-stem-cell-patent.html
Six Fa2N-4 Multicell Technologies / Xenotech Patents Active!
Inventor: Jin LiuRonald A. Faris
Current Assignee: Multicell Technologies
US 7566567 B2 Immortalized hepatocytes
Application granted
Status Active
2025-01-13 Adjusted expiration
https://patents.google.com/patent/US7566567B2/en?oq=7%2c566%2c567
Inventor: Jin Liu, Ronald A. Faris
Current Assignee: Multicell Technologies
EP 1704227 B1 IMMORTALIZED HEPATOCYTES
Doc Type: Granted Patent
Status Active
2024-10-07 Anticipated expiration
https://patents.google.com/patent/EP1704227B1/en?oq=EP1704227B1
Inventor: Jin Liu, Ronald A Faris
Current Assignee: Multicell Technologies Inc
EP1704227 A4 IMMORTALIZED HEPATOCYTES
Application granted
Status Active
2024-10-07 Anticipated expiration
https://patents.google.com/patent/EP1704227A4/en?oq=EP1704227A4
Inventor: Jin Liu, Ronald A Faris
Current Assignee: Multicell Technologies Inc
EP1704227 A1 IMMORTALIZED HEPATOCYTES
Application granted
Status Active
2024-10-07 Anticipated expiration
https://patents.google.com/patent/EP1704227A1/en?oq=EP1704227A1
Inventor: Jin LiuRonald A. Faris
Current Assignee: Multicell Technologies
DE 602004025380 D1 IMMORTALISIERTE HEPATOZYTEN
Doc Type: Granted Patent
Status Active
2024-10-08 Anticipated expiration
https://patents.google.com/patent/DE602004025380D1/en?oq=DE602004025380
Inventor: Jin LiuRonald Farie
Current Assignee: Multicell Technologies Inc
US20070004039 A1 Immortalized hepatocytes
2009-07-28 Application granted
Status Active
2025-01-13 Adjusted expiration
https://patents.google.com/patent/US20070004039A1/en?oq=US20070004039A1
"Gold Standard": Evaluation of a Novel Renewable Hepatic Cell Model for Prediction of Clinical CYP3A4 Induction Using a Correlation-Based RIS Approach https://investorshub.advfn.com/boards/read_msg.aspx?message_id=161354182
Family timeline https://www.lens.org/lens/patent/167-627-709-236-287/family
Immortalized Hepatocytes https://www.lens.org/lens/patent/167-627-709-236-28
$MCET Seven Patents Active: Multicell Technologies, Rhode Island Hospital and Xenotech ( SEKISUI XenoTech )
One Patent Multicell Technologies Receives Stem Cell Patent Active!
Inventor: Ronald A. Faris
Current Assignee: Rhode Island Hospital
US7935528 B2
Application granted
Status Active
2022-10-21 Adjusted expiration
https://patents.google.com/patent/US7935528B2/en?oq=7%2c935%2c528
The invention provides a primary liver stem cell and a cell doublet consisting of a hepatocyte and the stem cell, both of which are derived from normal liver tissue. Methods of isolating the cells, genetically altering the cells, and using the cells for transplantation are also within the invention.
https://www.patentdocs.org/2011/07/patent-profile-multicell-technologies-receives-stem-cell-patent.html
Six Fa2N-4 Multicell Technologies / Xenotech Patents Active!
Inventor: Jin LiuRonald A. Faris
Current Assignee: Multicell Technologies
US 7566567 B2 Immortalized hepatocytes
Application granted
Status Active
2025-01-13 Adjusted expiration
https://patents.google.com/patent/US7566567B2/en?oq=7%2c566%2c567
Inventor: Jin Liu, Ronald A. Faris
Current Assignee: Multicell Technologies
EP 1704227 B1 IMMORTALIZED HEPATOCYTES
Doc Type: Granted Patent
Status Active
2024-10-07 Anticipated expiration
https://patents.google.com/patent/EP1704227B1/en?oq=EP1704227B1
Inventor: Jin Liu, Ronald A Faris
Current Assignee: Multicell Technologies Inc
EP1704227 A4 IMMORTALIZED HEPATOCYTES
Application granted
Status Active
2024-10-07 Anticipated expiration
https://patents.google.com/patent/EP1704227A4/en?oq=EP1704227A4
Inventor: Jin Liu, Ronald A Faris
Current Assignee: Multicell Technologies Inc
EP1704227 A1 IMMORTALIZED HEPATOCYTES
Application granted
Status Active
2024-10-07 Anticipated expiration
https://patents.google.com/patent/EP1704227A1/en?oq=EP1704227A1
Inventor: Jin LiuRonald A. Faris
Current Assignee: Multicell Technologies
DE 602004025380 D1 IMMORTALISIERTE HEPATOZYTEN
Doc Type: Granted Patent
Status Active
2024-10-08 Anticipated expiration
https://patents.google.com/patent/DE602004025380D1/en?oq=DE602004025380
Inventor: Jin LiuRonald Farie
Current Assignee: Multicell Technologies Inc
US20070004039 A1 Immortalized hepatocytes
2009-07-28 Application granted
Status Active
2025-01-13 Adjusted expiration
https://patents.google.com/patent/US20070004039A1/en?oq=US20070004039A1
"Gold Standard": Evaluation of a Novel Renewable Hepatic Cell Model for Prediction of Clinical CYP3A4 Induction Using a Correlation-Based RIS Approach https://investorshub.advfn.com/boards/read_msg.aspx?message_id=161354182
Family timeline https://www.lens.org/lens/patent/167-627-709-236-287/family
Immortalized Hepatocytes https://www.lens.org/lens/patent/167-627-709-236-28
Market Makers decide! It's going up! Purchase offers confirmed! https://investorshub.advfn.com/MultiCell-Technologies-MCET-2694/
Market Makers decide! It's going up! Purchase offers confirmed! https://investorshub.advfn.com/MultiCell-Technologies-MCET-2694/
Before you look at the date first, you should read the contents and then put all the information together.
$MCET MultiCell has licensed several pharmaceutical companies rights to use the Fa2N-4 cell line for drug toxicity applications including Pfizer, Bristol-Myers Squibb, and Eisai Pharmaceuticals. MultiCell licensed Corning, Inc. to sell the Fa2N-4 cell line and media within the drug discovery and life science research markets for drug toxicity (Tox) applications as well as for drug adsorption, distribution, metabolism and excretion (ADME) studies.
MultiCell retained worldwide exclusive ownership of the Fa2N-4 and Ea1C-35 cell lines for all applications other than ADME/Tox, including drug target identification and using the cell lines for the production of therapeutic plasma proteins.
https://www.thefreelibrary.com/MultiCell+Technologies+is+granted+United+States+Patent+for...-a0214398995
$MCET MultiCell has licensed several pharmaceutical companies rights to use the Fa2N-4 cell line for drug toxicity applications including Pfizer, Bristol-Myers Squibb, and Eisai Pharmaceuticals. MultiCell licensed Corning, Inc. to sell the Fa2N-4 cell line and media within the drug discovery and life science research markets for drug toxicity (Tox) applications as well as for drug adsorption, distribution, metabolism and excretion (ADME) studies.
MultiCell retained worldwide exclusive ownership of the Fa2N-4 and Ea1C-35 cell lines for all applications other than ADME/Tox, including drug target identification and using the cell lines for the production of therapeutic plasma proteins.
https://www.thefreelibrary.com/MultiCell+Technologies+is+granted+United+States+Patent+for...-a0214398995
MultiCell has licensed several pharmaceutical companies rights to use the Fa2N-4 cell line for drug toxicity applications including Pfizer, Bristol-Myers Squibb, and Eisai Pharmaceuticals. MultiCell licensed Corning, Inc. to sell the Fa2N-4 cell line and media within the drug discovery and life science research markets for drug toxicity (Tox) applications as well as for drug adsorption, distribution, metabolism and excretion (ADME) studies.
MultiCell retained worldwide exclusive ownership of the Fa2N-4 and Ea1C-35 cell lines for all applications other than ADME/Tox, including drug target identification and using the cell lines for the production of therapeutic plasma proteins.
https://www.thefreelibrary.com/MultiCell+Technologies+is+granted+United+States+Patent+for...-a0214398995
Multicell Technologies makes money with Pfizer!
Patent: EP1893609A1 Current Assignee: Pfizer Inc
All results were compared to 100% activation control, i.e. cells treated only with cortisone (no inhibitors added). Human Fa2N-4 Immortalized Cell-Based Assay Fa2N-4 is a cell line derived from human hepatocytes, developed by MultiCell Technologies, Inc. (US Patent No. 6,107,043), and commercialized by XenoTech LLC via an exclusive license.
https://patents.google.com/patent/EP1893609A1/en
For me it is about facts or even said truths, and that's why I take the time for them as best I can. Facts are based on searches on the Internet. Because of the MCET website, I don't believe in that at all. How so? Truth???? AND THAT'S MY OPINION!
Answer to that! MultiCell Takes Control of Cell Marketing Program
https://www.businesswire.com/news/home/20060206005451/en/MultiCell-Takes-Control-of-Cell-Marketing-Program
It was recently deleted! Why???
About Adcetris® (Brentuximab vedotin) and Multicell Technologies:
Many Thanks! I've already marked you.
$MCET Seven Patents Active: Multicell Technologies, Rhode Island Hospital and Xenotech ( SEKISUI XenoTech )
One Patent Multicell Technologies Receives Stem Cell Patent Active!
Inventor: Ronald A. Faris
Current Assignee: Rhode Island Hospital
US7935528 B2
Application granted
Status Active
2022-10-21 Adjusted expiration
https://patents.google.com/patent/US7935528B2/en?oq=7%2c935%2c528
The invention provides a primary liver stem cell and a cell doublet consisting of a hepatocyte and the stem cell, both of which are derived from normal liver tissue. Methods of isolating the cells, genetically altering the cells, and using the cells for transplantation are also within the invention.
https://www.patentdocs.org/2011/07/patent-profile-multicell-technologies-receives-stem-cell-patent.html
Six Fa2N-4 Multicell Technologies / Xenotech Patents Active!
Inventor: Jin LiuRonald A. Faris
Current Assignee: Multicell Technologies
US 7566567 B2 Immortalized hepatocytes
Application granted
Status Active
2025-01-13 Adjusted expiration
https://patents.google.com/patent/US7566567B2/en?oq=7%2c566%2c567
Inventor: Jin Liu, Ronald A. Faris
Current Assignee: Multicell Technologies
EP 1704227 B1 IMMORTALIZED HEPATOCYTES
Doc Type: Granted Patent
Status Active
2024-10-07 Anticipated expiration
https://patents.google.com/patent/EP1704227B1/en?oq=EP1704227B1
Inventor: Jin Liu, Ronald A Faris
Current Assignee: Multicell Technologies Inc
EP1704227 A4 IMMORTALIZED HEPATOCYTES
Application granted
Status Active
2024-10-07 Anticipated expiration
https://patents.google.com/patent/EP1704227A4/en?oq=EP1704227A4
Inventor: Jin Liu, Ronald A Faris
Current Assignee: Multicell Technologies Inc
EP1704227 A1 IMMORTALIZED HEPATOCYTES
Application granted
Status Active
2024-10-07 Anticipated expiration
https://patents.google.com/patent/EP1704227A1/en?oq=EP1704227A1
Inventor: Jin LiuRonald A. Faris
Current Assignee: Multicell Technologies
DE 602004025380 D1 IMMORTALISIERTE HEPATOZYTEN
Doc Type: Granted Patent
Status Active
2024-10-08 Anticipated expiration
https://patents.google.com/patent/DE602004025380D1/en?oq=DE602004025380
Inventor: Jin LiuRonald Farie
Current Assignee: Multicell Technologies Inc
US20070004039 A1 Immortalized hepatocytes
2009-07-28 Application granted
Status Active
2025-01-13 Adjusted expiration
https://patents.google.com/patent/US20070004039A1/en?oq=US20070004039A1
"Gold Standard": Evaluation of a Novel Renewable Hepatic Cell Model for Prediction of Clinical CYP3A4 Induction Using a Correlation-Based RIS Approach https://investorshub.advfn.com/boards/read_msg.aspx?message_id=161354182
Family timeline https://www.lens.org/lens/patent/167-627-709-236-287/family
Immortalized Hepatocytes https://www.lens.org/lens/patent/167-627-709-236-28
$MCET Seven Patents Active: Multicell Technologies, Rhode Island Hospital and Xenotech ( SEKISUI XenoTech )
One Patent Multicell Technologies Receives Stem Cell Patent Active!
Inventor: Ronald A. Faris
Current Assignee: Rhode Island Hospital
US7935528 B2
Application granted
Status Active
2022-10-21 Adjusted expiration
https://patents.google.com/patent/US7935528B2/en?oq=7%2c935%2c528
The invention provides a primary liver stem cell and a cell doublet consisting of a hepatocyte and the stem cell, both of which are derived from normal liver tissue. Methods of isolating the cells, genetically altering the cells, and using the cells for transplantation are also within the invention.
https://www.patentdocs.org/2011/07/patent-profile-multicell-technologies-receives-stem-cell-patent.html
Six Fa2N-4 Multicell Technologies / Xenotech Patents Active!
Inventor: Jin LiuRonald A. Faris
Current Assignee: Multicell Technologies
US 7566567 B2 Immortalized hepatocytes
Application granted
Status Active
2025-01-13 Adjusted expiration
https://patents.google.com/patent/US7566567B2/en?oq=7%2c566%2c567
Inventor: Jin Liu, Ronald A. Faris
Current Assignee: Multicell Technologies
EP 1704227 B1 IMMORTALIZED HEPATOCYTES
Doc Type: Granted Patent
Status Active
2024-10-07 Anticipated expiration
https://patents.google.com/patent/EP1704227B1/en?oq=EP1704227B1
Inventor: Jin Liu, Ronald A Faris
Current Assignee: Multicell Technologies Inc
EP1704227 A4 IMMORTALIZED HEPATOCYTES
Application granted
Status Active
2024-10-07 Anticipated expiration
https://patents.google.com/patent/EP1704227A4/en?oq=EP1704227A4
Inventor: Jin Liu, Ronald A Faris
Current Assignee: Multicell Technologies Inc
EP1704227 A1 IMMORTALIZED HEPATOCYTES
Application granted
Status Active
2024-10-07 Anticipated expiration
https://patents.google.com/patent/EP1704227A1/en?oq=EP1704227A1
Inventor: Jin LiuRonald A. Faris
Current Assignee: Multicell Technologies
DE 602004025380 D1 IMMORTALISIERTE HEPATOZYTEN
Doc Type: Granted Patent
Status Active
2024-10-08 Anticipated expiration
https://patents.google.com/patent/DE602004025380D1/en?oq=DE602004025380
Inventor: Jin LiuRonald Farie
Current Assignee: Multicell Technologies Inc
US20070004039 A1 Immortalized hepatocytes
2009-07-28 Application granted
Status Active
2025-01-13 Adjusted expiration
https://patents.google.com/patent/US20070004039A1/en?oq=US20070004039A1
"Gold Standard": Evaluation of a Novel Renewable Hepatic Cell Model for Prediction of Clinical CYP3A4 Induction Using a Correlation-Based RIS Approach https://investorshub.advfn.com/boards/read_msg.aspx?message_id=161354182
Family timeline https://www.lens.org/lens/patent/167-627-709-236-287/family
Immortalized Hepatocytes https://www.lens.org/lens/patent/167-627-709-236-28
$MCET Acknowledgments: We thank Ronald A. Faris, Jin Liu, Stephanie Cascio, Henry Santangini, Kathy Garcia, and Paul Silva of MultiCell Technologies for the Fa2N-4 clone and the scientific collaborations; Sharon Ripp of Pfizer Groton Laboratories for contribution to CYP3A4 enzyme activity data; Teresa Jenkinson and Mike Banker of Pfizer Groton Laboratories for the photomicrograph of the Fa2N-4 cells; Kelly Longo of Pfizer Strategic Alliances for support; and Bo Feng, Ronald Scott Obach, and Ted Liston of Pfizer Groton Laboratories for suggestions and critical reading of this manuscript.
Induction of Drug Metabolism Enzymes and MDR1 Using a Novel Human Hepatocyte Cell Line
https://s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/821/original/303.full.pdf?1539359418
$MCET Acknowledgments: We thank Ronald A. Faris, Jin Liu, Stephanie Cascio, Henry Santangini, Kathy Garcia, and Paul Silva of MultiCell Technologies for the Fa2N-4 clone and the scientific collaborations; Sharon Ripp of Pfizer Groton Laboratories for contribution to CYP3A4 enzyme activity data; Teresa Jenkinson and Mike Banker of Pfizer Groton Laboratories for the photomicrograph of the Fa2N-4 cells; Kelly Longo of Pfizer Strategic Alliances for support; and Bo Feng, Ronald Scott Obach, and Ted Liston of Pfizer Groton Laboratories for suggestions and critical reading of this manuscript.
Induction of Drug Metabolism Enzymes and MDR1 Using a Novel Human Hepatocyte Cell Line
https://s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/821/original/303.full.pdf?1539359418
$MCET "Gold Standard": Evaluation of a Novel Renewable Hepatic Cell Model for Prediction of Clinical CYP3A4 Induction Using a Correlation-Based RIS Approach
Jin Liu, Ronald A Faris
Abstract
Metabolism enzyme induction-mediated drug-drug interactions need to be carefully characterized in vitro for drug candidates in order to predict in vivo outcomes of safety risk and therapeutic efficiency. Currently, both the FDA and EMA recommend using primary human hepatocytes as the "Gold Standard" in vitro test system for studying the induction potential of candidate drugs on cytochrome P450 (CYP), CYP3A4, CYP1A2, and CYP2B6. However, primary human hepatocytes are known to bear inherent limitations such as limited supply and large lot-to-lot variations which result in an experimental burden to qualify new lots. To overcome these shortcomings, a renewable source of human hepatocytes (i.e., Corning HepatoCells) was developed from primary human hepatocytes and was evaluated for in vitro CYP3A4 induction using methods well established by pharmaceutical industry HepatoCells have shown mature hepatocyte-like morphology, demonstrated primary hepatocyte-like response to prototypical inducers of all 3 CYP enzymes with excellent consistency. Importantly, HepatoCells retain a phenobarbital responsive nuclear translocation of human CAR from the cytoplasm, characteristic to primary hepatocytes. To validate HepatoCells as a useful tool to predict potential clinical relevant CYP3A4 induction, we tested three different lots of HepatoCells with a group of clinical strong, moderate/weak CYP3A4 inducers, and non-inducers. A relative induction score (RIS) calibration curve based approach was used for prediction. HepatoCells showed accurate prediction comparable to primary human hepatocytes. Together, these results demonstrate that Corning HepatoCells is a reliable in vitro model for drug-drug interaction studies during the early phase of drug testing.
https://dmd.aspetjournals.org/content/early/2017/01/06/dmd.116.072124
https://dmd.aspetjournals.org/content/dmd/early/2017/01/06/dmd.116.072124.full.pdf
Currently, both the FDA and EMA recommend using primary human hepatocytes as the "Gold Standard" in vitro test system for studying the induction potential of candidate drugs on cytochrome P450 (CYP), CYP3A4, CYP1A2, and CYP2B6.
Fa2N-4 Multicell Technologies / Xenotech Patents
Inventor: Jin Liu, Ronald A Faris
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=161330062
$MCET "Gold Standard": Evaluation of a Novel Renewable Hepatic Cell Model for Prediction of Clinical CYP3A4 Induction Using a Correlation-Based RIS Approach
Jin Liu, Ronald A Faris
Abstract
Metabolism enzyme induction-mediated drug-drug interactions need to be carefully characterized in vitro for drug candidates in order to predict in vivo outcomes of safety risk and therapeutic efficiency. Currently, both the FDA and EMA recommend using primary human hepatocytes as the "Gold Standard" in vitro test system for studying the induction potential of candidate drugs on cytochrome P450 (CYP), CYP3A4, CYP1A2, and CYP2B6. However, primary human hepatocytes are known to bear inherent limitations such as limited supply and large lot-to-lot variations which result in an experimental burden to qualify new lots. To overcome these shortcomings, a renewable source of human hepatocytes (i.e., Corning HepatoCells) was developed from primary human hepatocytes and was evaluated for in vitro CYP3A4 induction using methods well established by pharmaceutical industry HepatoCells have shown mature hepatocyte-like morphology, demonstrated primary hepatocyte-like response to prototypical inducers of all 3 CYP enzymes with excellent consistency. Importantly, HepatoCells retain a phenobarbital responsive nuclear translocation of human CAR from the cytoplasm, characteristic to primary hepatocytes. To validate HepatoCells as a useful tool to predict potential clinical relevant CYP3A4 induction, we tested three different lots of HepatoCells with a group of clinical strong, moderate/weak CYP3A4 inducers, and non-inducers. A relative induction score (RIS) calibration curve based approach was used for prediction. HepatoCells showed accurate prediction comparable to primary human hepatocytes. Together, these results demonstrate that Corning HepatoCells is a reliable in vitro model for drug-drug interaction studies during the early phase of drug testing.
https://dmd.aspetjournals.org/content/early/2017/01/06/dmd.116.072124
https://dmd.aspetjournals.org/content/dmd/early/2017/01/06/dmd.116.072124.full.pdf
Currently, both the FDA and EMA recommend using primary human hepatocytes as the "Gold Standard" in vitro test system for studying the induction potential of candidate drugs on cytochrome P450 (CYP), CYP3A4, CYP1A2, and CYP2B6.
Fa2N-4 Multicell Technologies / Xenotech Patents
Inventor: Jin Liu, Ronald A Faris
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=161330062
No problem! Thx for this info!
EV merger Current Idglobal and Noveda technologies? Any info?
$MCET Seven Patents Active: Multicell Technologies, Rhode Island Hospital and Xenotech ( SEKISUI XenoTech )
One Patent Multicell Technologies Receives Stem Cell Patent Active!
Inventor: Ronald A. Faris
Current Assignee: Rhode Island Hospital
US7935528 B2
Application granted
Status Active
2022-10-21 Adjusted expiration
https://patents.google.com/patent/US7935528B2/en?oq=7%2c935%2c528
The invention provides a primary liver stem cell and a cell doublet consisting of a hepatocyte and the stem cell, both of which are derived from normal liver tissue. Methods of isolating the cells, genetically altering the cells, and using the cells for transplantation are also within the invention.
https://www.patentdocs.org/2011/07/patent-profile-multicell-technologies-receives-stem-cell-patent.html
Six Fa2N-4 Multicell Technologies / Xenotech Patents Active!
Inventor: Jin LiuRonald A. Faris
Current Assignee: Multicell Technologies
US 7566567 B2 Immortalized hepatocytes
Application granted
Status Active
2025-01-13 Adjusted expiration
https://patents.google.com/patent/US7566567B2/en?oq=7%2c566%2c567
Inventor: Jin Liu, Ronald A. Faris
Current Assignee: Multicell Technologies
EP 1704227 B1 IMMORTALIZED HEPATOCYTES
Doc Type: Granted Patent
Status Active
2024-10-07 Anticipated expiration
https://patents.google.com/patent/EP1704227B1/en?oq=EP1704227B1
Inventor: Jin Liu, Ronald A Faris
Current Assignee: Multicell Technologies Inc
EP1704227 A4 IMMORTALIZED HEPATOCYTES
Application granted
Status Active
2024-10-07 Anticipated expiration
https://patents.google.com/patent/EP1704227A4/en?oq=EP1704227A4
Inventor: Jin Liu, Ronald A Faris
Current Assignee: Multicell Technologies Inc
EP1704227 A1 IMMORTALIZED HEPATOCYTES
Application granted
Status Active
2024-10-07 Anticipated expiration
https://patents.google.com/patent/EP1704227A1/en?oq=EP1704227A1
Inventor: Jin LiuRonald A. Faris
Current Assignee: Multicell Technologies
DE 602004025380 D1 IMMORTALISIERTE HEPATOZYTEN
Doc Type: Granted Patent
Status Active
2024-10-08 Anticipated expiration
https://patents.google.com/patent/DE602004025380D1/en?oq=DE602004025380
Inventor: Jin LiuRonald Farie
Current Assignee: Multicell Technologies Inc
US20070004039 A1 Immortalized hepatocytes
2009-07-28 Application granted
Status Active
2025-01-13 Adjusted expiration
https://patents.google.com/patent/US20070004039A1/en?oq=US20070004039A1
"Gold Standard": Evaluation of a Novel Renewable Hepatic Cell Model for Prediction of Clinical CYP3A4 Induction Using a Correlation-Based RIS Approach https://investorshub.advfn.com/boards/read_msg.aspx?message_id=161354182
Family timeline https://www.lens.org/lens/patent/167-627-709-236-287/family
Immortalized Hepatocytes https://www.lens.org/lens/patent/167-627-709-236-28
$MCET Seven Patents Active: Multicell Technologies, Rhode Island Hospital and Xenotech ( SEKISUI XenoTech )
One Patent Multicell Technologies Receives Stem Cell Patent Active!
Inventor: Ronald A. Faris
Current Assignee: Rhode Island Hospital
US7935528 B2
Application granted
Status Active
2022-10-21 Adjusted expiration
https://patents.google.com/patent/US7935528B2/en?oq=7%2c935%2c528
The invention provides a primary liver stem cell and a cell doublet consisting of a hepatocyte and the stem cell, both of which are derived from normal liver tissue. Methods of isolating the cells, genetically altering the cells, and using the cells for transplantation are also within the invention.
https://www.patentdocs.org/2011/07/patent-profile-multicell-technologies-receives-stem-cell-patent.html
Six Fa2N-4 Multicell Technologies / Xenotech Patents Active!
Inventor: Jin LiuRonald A. Faris
Current Assignee: Multicell Technologies
US 7566567 B2 Immortalized hepatocytes
Application granted
Status Active
2025-01-13 Adjusted expiration
https://patents.google.com/patent/US7566567B2/en?oq=7%2c566%2c567
Inventor: Jin Liu, Ronald A. Faris
Current Assignee: Multicell Technologies
EP 1704227 B1 IMMORTALIZED HEPATOCYTES
Doc Type: Granted Patent
Status Active
2024-10-07 Anticipated expiration
https://patents.google.com/patent/EP1704227B1/en?oq=EP1704227B1
Inventor: Jin Liu, Ronald A Faris
Current Assignee: Multicell Technologies Inc
EP1704227 A4 IMMORTALIZED HEPATOCYTES
Application granted
Status Active
2024-10-07 Anticipated expiration
https://patents.google.com/patent/EP1704227A4/en?oq=EP1704227A4
Inventor: Jin Liu, Ronald A Faris
Current Assignee: Multicell Technologies Inc
EP1704227 A1 IMMORTALIZED HEPATOCYTES
Application granted
Status Active
2024-10-07 Anticipated expiration
https://patents.google.com/patent/EP1704227A1/en?oq=EP1704227A1
Inventor: Jin LiuRonald A. Faris
Current Assignee: Multicell Technologies
DE 602004025380 D1 IMMORTALISIERTE HEPATOZYTEN
Doc Type: Granted Patent
Status Active
2024-10-08 Anticipated expiration
https://patents.google.com/patent/DE602004025380D1/en?oq=DE602004025380
Inventor: Jin LiuRonald Farie
Current Assignee: Multicell Technologies Inc
US20070004039 A1 Immortalized hepatocytes
2009-07-28 Application granted
Status Active
2025-01-13 Adjusted expiration
https://patents.google.com/patent/US20070004039A1/en?oq=US20070004039A1
"Gold Standard": Evaluation of a Novel Renewable Hepatic Cell Model for Prediction of Clinical CYP3A4 Induction Using a Correlation-Based RIS Approach https://investorshub.advfn.com/boards/read_msg.aspx?message_id=161354182
Family timeline https://www.lens.org/lens/patent/167-627-709-236-287/family
Immortalized Hepatocytes https://www.lens.org/lens/patent/167-627-709-236-28
$MCET Acknowledgments: We thank Ronald A. Faris, Jin Liu, Stephanie Cascio, Henry Santangini, Kathy Garcia, and Paul Silva of MultiCell Technologies for the Fa2N-4 clone and the scientific collaborations; Sharon Ripp of Pfizer Groton Laboratories for contribution to CYP3A4 enzyme activity data; Teresa Jenkinson and Mike Banker of Pfizer Groton Laboratories for the photomicrograph of the Fa2N-4 cells; Kelly Longo of Pfizer Strategic Alliances for support; and Bo Feng, Ronald Scott Obach, and Ted Liston of Pfizer Groton Laboratories for suggestions and critical reading of this manuscript.
Induction of Drug Metabolism Enzymes and MDR1 Using a Novel Human Hepatocyte Cell Line
https://s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/821/original/303.full.pdf?1539359418
$MCET Acknowledgments: We thank Ronald A. Faris, Jin Liu, Stephanie Cascio, Henry Santangini, Kathy Garcia, and Paul Silva of MultiCell Technologies for the Fa2N-4 clone and the scientific collaborations; Sharon Ripp of Pfizer Groton Laboratories for contribution to CYP3A4 enzyme activity data; Teresa Jenkinson and Mike Banker of Pfizer Groton Laboratories for the photomicrograph of the Fa2N-4 cells; Kelly Longo of Pfizer Strategic Alliances for support; and Bo Feng, Ronald Scott Obach, and Ted Liston of Pfizer Groton Laboratories for suggestions and critical reading of this manuscript.
Induction of Drug Metabolism Enzymes and MDR1 Using a Novel Human Hepatocyte Cell Line
https://s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/821/original/303.full.pdf?1539359418
$MCET "Gold Standard": Evaluation of a Novel Renewable Hepatic Cell Model for Prediction of Clinical CYP3A4 Induction Using a Correlation-Based RIS Approach
Jin Liu, Ronald A Faris
Abstract
Metabolism enzyme induction-mediated drug-drug interactions need to be carefully characterized in vitro for drug candidates in order to predict in vivo outcomes of safety risk and therapeutic efficiency. Currently, both the FDA and EMA recommend using primary human hepatocytes as the "Gold Standard" in vitro test system for studying the induction potential of candidate drugs on cytochrome P450 (CYP), CYP3A4, CYP1A2, and CYP2B6. However, primary human hepatocytes are known to bear inherent limitations such as limited supply and large lot-to-lot variations which result in an experimental burden to qualify new lots. To overcome these shortcomings, a renewable source of human hepatocytes (i.e., Corning HepatoCells) was developed from primary human hepatocytes and was evaluated for in vitro CYP3A4 induction using methods well established by pharmaceutical industry HepatoCells have shown mature hepatocyte-like morphology, demonstrated primary hepatocyte-like response to prototypical inducers of all 3 CYP enzymes with excellent consistency. Importantly, HepatoCells retain a phenobarbital responsive nuclear translocation of human CAR from the cytoplasm, characteristic to primary hepatocytes. To validate HepatoCells as a useful tool to predict potential clinical relevant CYP3A4 induction, we tested three different lots of HepatoCells with a group of clinical strong, moderate/weak CYP3A4 inducers, and non-inducers. A relative induction score (RIS) calibration curve based approach was used for prediction. HepatoCells showed accurate prediction comparable to primary human hepatocytes. Together, these results demonstrate that Corning HepatoCells is a reliable in vitro model for drug-drug interaction studies during the early phase of drug testing.
https://dmd.aspetjournals.org/content/early/2017/01/06/dmd.116.072124
https://dmd.aspetjournals.org/content/dmd/early/2017/01/06/dmd.116.072124.full.pdf
Currently, both the FDA and EMA recommend using primary human hepatocytes as the "Gold Standard" in vitro test system for studying the induction potential of candidate drugs on cytochrome P450 (CYP), CYP3A4, CYP1A2, and CYP2B6.
Fa2N-4 Multicell Technologies / Xenotech Patents
Inventor: Jin Liu, Ronald A Faris
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=161330062
$MCET "Gold Standard": Evaluation of a Novel Renewable Hepatic Cell Model for Prediction of Clinical CYP3A4 Induction Using a Correlation-Based RIS Approach
Jin Liu, Ronald A Faris
Abstract
Metabolism enzyme induction-mediated drug-drug interactions need to be carefully characterized in vitro for drug candidates in order to predict in vivo outcomes of safety risk and therapeutic efficiency. Currently, both the FDA and EMA recommend using primary human hepatocytes as the "Gold Standard" in vitro test system for studying the induction potential of candidate drugs on cytochrome P450 (CYP), CYP3A4, CYP1A2, and CYP2B6. However, primary human hepatocytes are known to bear inherent limitations such as limited supply and large lot-to-lot variations which result in an experimental burden to qualify new lots. To overcome these shortcomings, a renewable source of human hepatocytes (i.e., Corning HepatoCells) was developed from primary human hepatocytes and was evaluated for in vitro CYP3A4 induction using methods well established by pharmaceutical industry HepatoCells have shown mature hepatocyte-like morphology, demonstrated primary hepatocyte-like response to prototypical inducers of all 3 CYP enzymes with excellent consistency. Importantly, HepatoCells retain a phenobarbital responsive nuclear translocation of human CAR from the cytoplasm, characteristic to primary hepatocytes. To validate HepatoCells as a useful tool to predict potential clinical relevant CYP3A4 induction, we tested three different lots of HepatoCells with a group of clinical strong, moderate/weak CYP3A4 inducers, and non-inducers. A relative induction score (RIS) calibration curve based approach was used for prediction. HepatoCells showed accurate prediction comparable to primary human hepatocytes. Together, these results demonstrate that Corning HepatoCells is a reliable in vitro model for drug-drug interaction studies during the early phase of drug testing.
https://dmd.aspetjournals.org/content/early/2017/01/06/dmd.116.072124
https://dmd.aspetjournals.org/content/dmd/early/2017/01/06/dmd.116.072124.full.pdf
Currently, both the FDA and EMA recommend using primary human hepatocytes as the "Gold Standard" in vitro test system for studying the induction potential of candidate drugs on cytochrome P450 (CYP), CYP3A4, CYP1A2, and CYP2B6.
Fa2N-4 Multicell Technologies / Xenotech Patents
Inventor: Jin Liu, Ronald A Faris
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=161330062
Acknowledgments: We thank Ronald A. Faris, Jin Liu, Stephanie Cascio, Henry Santangini, Kathy Garcia, and Paul Silva of MultiCell Technologies for the Fa2N-4 clone and the scientific collaborations; Sharon Ripp of Pfizer Groton Laboratories for contribution to CYP3A4 enzyme activity data; Teresa Jenkinson and Mike Banker of Pfizer Groton Laboratories for the photomicrograph of the Fa2N-4 cells; Kelly Longo of Pfizer Strategic Alliances for support; and Bo Feng, Ronald Scott Obach, and Ted Liston of Pfizer Groton Laboratories for suggestions and critical reading of this manuscript.
Induction of Drug Metabolism Enzymes and MDR1 Using a Novel Human Hepatocyte Cell Line
https://s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/821/original/303.full.pdf?1539359418
Currently, both the FDA and EMA recommend using primary human hepatocytes as the "Gold Standard" in vitro test system for studying the induction potential of candidate drugs on cytochrome P450 (CYP), CYP3A4, CYP1A2, and CYP2B6.